Fraunhofer-Award

FHG Fraunhofer Gesellschaft
 
Joseph-von-Fraunhofer-Preis

Joseph-von-Fraunhofer-Preis
Two times winner of the Joseph-von-Fraunhofer Award

 
Welcome to RESprotect

RESprotect GmbH is a Dresden based, privately held Biotech company specialising in the development of drugs for the prevention and treatment of chemotherapeutic drug resistance and radiation therapy resistance.

RP101 is the company's first product candidate, a small molecule drug given orally to cancer patients in combination with standard of care chemotherapy. In two clinical studies, patients with advanced pancreatic cancer were shown to achieve significantly improved survival when compared to those receiving standard chemotherapy alone.

(http://www.resprotect.de/CASPASE 8, APOPTOSIS-RELATED CYSTEINE PROTEASE)

404: Not Found

Sorry, but the content you requested could not be found